Barclays analyst Peter Lawson raised the firm’s price target on ImmunoGen to $27 from $20 and keeps an Overweight rating on the shares. The analyst cites the company’s strong Q2 results and continued strong commercial launch in ovarian cancer for the target raise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMGN:
- ImmunoGen call volume above normal and directionally bullish
- ImmunoGen price target raised to $25 from $23 at Canaccord
- ImmunoGen price target raised to $26 from $21 at H.C. Wainwright
- ImmunoGen announces departure of Chief Medical Officer Anna Berkenblit
- ImmunoGen raises FY23 OpExp view to $350M-$365M from $320M-$335M